Home > Insider Trading > Filing (0001104659-23-009464)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1709401	Rubius Therapeutics Inc.	RUBY	Biological Products, (No Disgnostic Substances) (2836)	042688109

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1874962	Dannielle Appelhans	C/O Verdolino &Amp; Lowey, P.c. 124 Washington St. Foxborough MA 02035	Ceo And President	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2023-01-31	7,500	$0.00	14,263	No	4	M	Direct
Common Stock	Disposition	2023-02-01	3,878	$0.25	10,385	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Units	Disposition	2023-01-31	7,500	$0.00	7,500	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
22,500			No	4	M	Direct

Footnotes

Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units listed in Table II. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the reporting person.
The shares underlying the restricted stock units vest in four equal annual installments beginning on January 31, 2023.